ARDELYX, INC. (ARDX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 450.89M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 25.40M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $450.89M | $25.40M | (m) |
| 2026-03-31 | (m) | $427.68M | $32.05M | (m) |
| 2025-12-31 | (m) | $407.32M | $39.54M | (m) |
| 2025-09-30 | (m) | $398.23M | $46.95M | (m) |
| 2025-06-30 | (m) | $386.15M | $58.70M | (m) |
| 2025-03-31 | (m) | $361.71M | $55.73M | (m) |
| 2024-12-31 | (m) | $333.62M | $50.56M | (m) |
| 2024-09-30 | (m) | $251.85M | $37.37M | (m) |
| 2024-06-30 | (m) | $210.00M | $29.33M | (m) |
| 2024-03-31 | (m) | $159.11M | $23.39M | (m) |
| 2023-12-31 | (m) | $124.46M | $17.80M | (m) |
| 2023-09-30 | (m) | $134.27M | (m) | (m) |
| 2023-06-30 | (m) | $82.87M | (m) | (m) |
| 2023-03-31 | (m) | $63.06M | (m) | (m) |
| 2022-12-31 | (m) | $52.16M | (m) | (m) |
| 2022-09-30 | (m) | $9.01M | (m) | (m) |
| 2022-06-30 | (m) | $5.20M | (m) | (m) |
| 2022-03-31 | (m) | $3.98M | (m) | (m) |
| 2021-12-31 | (m) | $10.10M | (m) | (m) |
| 2021-09-30 | (m) | $10.88M | (m) | (m) |
| 2021-06-30 | (m) | $12.42M | (m) | (m) |
| 2021-03-31 | (m) | $12.94M | (m) | (m) |
| 2020-12-31 | (m) | $7.57M | (m) | (m) |
| 2020-09-30 | (m) | $8.01M | (m) | (m) |
| 2020-06-30 | (m) | $8.31M | (m) | (m) |
| 2020-03-31 | (m) | $6.49M | (m) | (m) |
| 2019-12-31 | $4.68M | $5.28M | (m) | 88.64% |
| 2019-09-30 | $2.52M | $3.12M | (m) | 80.74% |
| 2019-06-30 | $273.00K | $275.00K | (m) | 99.27% |
| 2018-12-31 | $2.14M | $2.61M | (m) | 82.13% |
| 2018-09-30 | $35.66M | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | $33.60M | $42.00M | (m) | 80.00% |
| 2015-12-31 | (m) | $24.03M | (m) | (m) |
| 2015-09-30 | (m) | $30.36M | (m) | (m) |
| 2015-06-30 | (m) | $37.96M | (m) | (m) |
| 2015-03-31 | (m) | $28.96M | (m) | (m) |
| 2014-12-31 | (m) | $31.62M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $30.92M | (m) | (m) |
| 2013-12-31 | (m) | $28.93M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $5.41M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |